MedTrace Logo

Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer

NCT07680088 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-07-02

No results posted yet for this study

Summary

The goal of this clinical trial is to see the safety and efficacy of pembrolizumab and lenvatinib in patients with anal squamous cell cancer that cannot be removed through surgery or is spread to other organs. Eligible participants should have also received some form of standard therapy previously for their advanced cancer.

Participants will be required to come for a clinic visit and infusion of pembrolizumab. Lenvatinib will be taken by mouth at home based on direction provided by physicians and research team.

Conditions

  • Anal Squamous Cell Carcinoma

Interventions

DRUG

Lenvatinib

20 mg orally daily on days 1-21

DRUG

Pembrolizumab

200 mg every Day 1 Intravenous every 21 days

Sponsors & Collaborators

Principal Investigators

  • Syed Kazmi, MD · Associate Professor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-09-30
Completion
2030-09-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07680088 on ClinicalTrials.gov